Genome News and Research

RSS

Copy number variants may cause autism: Study

An international consortium of researchers from more than 70 universities, including the University of Utah, has reported that a study of nearly 2,300 people supports the growing consensus that autism is caused in part by rare genetic changes called copy number variants (CNVs).

10 Jun 2010

New genetic discoveries from Autism Genome Project

An international consortium of researchers working under the auspices of Autism Speaks, the world's largest autism science and advocacy organization, has announced new genetic discoveries from the second phase of its collaborative study: the Autism Genome Project. The results were published today in the journal Nature, one of the world's most respected peer-reviewed scientific publications.

10 Jun 2010

World's largest DNA scan reveals new genetic changes in autistic children

The world's largest DNA scan for familial autism has uncovered new genetic changes in autistic children that are often not present in their parents. Identified in less than 1 percent of the population, these rare variants occur nearly 20 percent more in autistic children.

10 Jun 2010

Veracyte announces completion of Series B round

Veracyte, Inc. announced today the successful completion of its Series B round, a key milestone toward the company's first product launch later this year. The South San Francisco biotechnology company is committed to pioneering molecular cytology diagnostics to improve patient care and lower health care costs. This round was led by Domain Associates with significant participation from Veracyte's founding investors including Kleiner Perkins Caufield & Byers (KPCB), TPG Biotech (TPG), and Versant Ventures.

10 Jun 2010

Argus Optical Mapping System for microbial whole genome analysis launched at ASM 2010 General Meeting

OpGen, Inc., a microbial genomics solutions company, announced the launch of the Argus Optical Mapping System for microbial whole genome analysis at the ASM 2010 General Meeting held in San Diego, CA May 23-27, 2010. The Argus Optical Mapping System is based on Optical Mapping Technology which generates ordered, whole genome restriction maps from single DNA molecules.

10 Jun 2010

Autism is caused in part by CNVs: Study

10 Jun 2010

Scientists develop algorithm to predict gene sequence of kinases

Kinexus Bioinformatics Corporation, a world-leader in molecular communications research, announced major advancements in its PhosphoNET KnowledgeBase for the study of cell signalling systems. This free resource to the scientific community now features data on more than 92,000 human phosphorylation sites, including their occurrence in over 20 other diverse species, and identification of the protein kinases that target these regulatory sites.

9 Jun 2010

CGH, FISH techniques effective for postmortem analysis of fetuses, infants with congenital anomalies

New techniques to detect chromosomal abnormalities can offer a higher degree of accuracy. Chromosomal abnormalities are a well-known cause of multiple congenital anomalies, and conventional methods of culture analysis have proven unsuccessful in 10% to 40% of cases. Comparative genomic hybridization (CGH) and fluorescent in situ hybridization (FISH) techniques were tested and found successful by analyzing tissue from children who had multiple congenital anomalies.

9 Jun 2010

New report compares U.S. and European funding for research related to synthetic biology

A new analysis by the Synthetic Biology Project at the Woodrow Wilson Center found that the U.S. government has spent around $430 million on research related to synthetic biology since 2005, with the Department of Energy funding a majority of the research. By comparison, the analysis indicated that the European Union and three individual European countries – the Netherlands, United Kingdom, and Germany – had spent approximately $160 million during that same period.

9 Jun 2010

Human Genome Sciences reports results of mapatumumab Phase 2 trial for multiple myeloma

Human Genome Sciences, Inc. today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with bortezomib (Velcade) in patients with advanced multiple myeloma.

9 Jun 2010

Cellectis bioresearch, Lonza collaborate in development, commercialization of bioengineered cell line

Cellectis bioresearch, the French genome customization specialist and a commercial subsidiary of Cellectis, and Lonza, a world leader in biotechnology production, announce today that the companies have entered into an agreement for the development and commercialization of a bioengineered cell line.

9 Jun 2010

NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates

NanoViricides, Inc. reports that its anti-HIV drug candidates demonstrated efficacy in the recently completed cell culture studies using two distinctly different HIV-1 isolates. The studies were performed in the laboratory of Carol Lackman-Smith at the Southern Research Institute, Frederick, Maryland.

8 Jun 2010

Princeton University president named 2010 winner of Henry G. Friesen International Prize in Health Research

Internationally renowned scientist and scholar Shirley M. Tilghman, president of Princeton University, was named the 2010 winner of the Henry G. Friesen International Prize in Health Research.

8 Jun 2010

Takeda Rika Kogyo to distribute WaferGen's SmartChip Real-Time PCR System in Japan

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genome analysis systems, today announced the signing of an exclusive distribution agreement for the company's SmartChip Real-Time PCR System with Takeda Rika Kogyo Co., Ltd., a leading distributor of innovative products and services in the life science markets within Japan.

8 Jun 2010

Gene variant linked to ability of Tibetans to cope with low-oxygen conditions identified

A new study pinpoints the genetic changes that enable Tibetans to thrive at altitudes where others get sick.

8 Jun 2010

Chronix' DNA blood tests detect prostate, breast cancer with 92% sensitivity and 100% specificity

Chronix Biomedical today reported new data further demonstrating that its DNA blood tests have the potential to accurately detect early stage breast and prostate cancers. Chronix's proprietary technology identifies disease-specific genetic fingerprints based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells.

8 Jun 2010

Protein p53 becomes activated to control creation of ova and spermatozoids: Study

Protein 53 is very important in protecting against cancer given that it prevents cancer-causing mutations from accumulating and its inactivation is closely linked to the proliferation of tumour cells. UAB lecturer Ignasi Roig participated in the study. Formed by an international research team, the study served to discover that this protein played an unexpected physiological role: it also becomes activated during the formation process of ova and spermatozoids.

8 Jun 2010

Genetic mutations help predict risk of prostate cancer in younger men: Researchers

Prostate cancer has become more common in younger men, and it's often more aggressive in these men. A new study from researchers at the University of Michigan Comprehensive Cancer Center has found that a series of genetic mutations could help detect this early onset prostate cancer.

8 Jun 2010

Chronix's serum DNA assays have potential to detect early stage breast cancer, prostate cancer

Chronix Biomedical today reported new data further demonstrating that its serum DNA blood tests have the potential to accurately detect early stage breast cancer and prostate cancer. Chronix's proprietary technology identifies disease-specific genetic fingerprints based on circulating DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells.

7 Jun 2010

GSK submits BENLYSTA MAA for systemic lupus erythematosus

Human Genome Sciences, Inc. today announced that GlaxoSmithKline (GSK) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval to market BENLYSTA® (belimumab) for the treatment of systemic lupus erythematosus (SLE).

7 Jun 2010

Genome News and Research

Copy number variants may cause autism: Study

New genetic discoveries from Autism Genome Project

World's largest DNA scan reveals new genetic changes in autistic children

Veracyte announces completion of Series B round

Argus Optical Mapping System for microbial whole genome analysis launched at ASM 2010 General Meeting

Autism is caused in part by CNVs: Study

Scientists develop algorithm to predict gene sequence of kinases

CGH, FISH techniques effective for postmortem analysis of fetuses, infants with congenital anomalies

New report compares U.S. and European funding for research related to synthetic biology

Human Genome Sciences reports results of mapatumumab Phase 2 trial for multiple myeloma

Cellectis bioresearch, Lonza collaborate in development, commercialization of bioengineered cell line

NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates

Princeton University president named 2010 winner of Henry G. Friesen International Prize in Health Research

Takeda Rika Kogyo to distribute WaferGen's SmartChip Real-Time PCR System in Japan

Gene variant linked to ability of Tibetans to cope with low-oxygen conditions identified

Chronix' DNA blood tests detect prostate, breast cancer with 92% sensitivity and 100% specificity

Protein p53 becomes activated to control creation of ova and spermatozoids: Study

Genetic mutations help predict risk of prostate cancer in younger men: Researchers

Chronix's serum DNA assays have potential to detect early stage breast cancer, prostate cancer

GSK submits BENLYSTA MAA for systemic lupus erythematosus

Genetics & Genomics - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News